In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 11 to 20 of 22

TitleTypeExpected publication date
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]Technology appraisal guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)Technology appraisal guidanceTBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All